Company Profile
AP Biosciences researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration.
Its portfolio also includes AP505 that is in phase I clinical trials for treating solid tumors, AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas, AP402, which is in the pre-clinical research phase for breast cancer patients, and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and solid tumors.
It caters to healthcare and biotechnology industries. AP Biosciences, Inc. has strategic collaboration with Delos Capital to discover and develop novel immune-related drug candidates through early clinical proof of concept. Founded in 2013, the company is based in Taipei, Taiwan.